Find verified Orforglipron API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Orforglipron for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Orforglipron API.
Alternate Names: LY3502970, OWL833, GLP-1 receptor agonist 1
CAS No: 2212020-52-3
Mol Formula: C48H48F2N10O5
Mol Weight: 883.0 g/mol
IUPAC Name: 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl -Show More
API Description: Orforglipron is an oral, non-peptide, small-molecule GLP-1 receptor agonist being developed by Eli Lilly for the treatment of type 2 diabetes and obesity. It was discovered by Chugai Pharmaceutical and licensed to Lilly in 2018. Orforglipron is designed to be a once-daily oral medication, and clinical trials have shown promising results for both weight loss and HbA1c reduction in patients with type 2 diabetes and obesity.
